S&P 500   0.67 (+1.82%)
DOW   0.67 (+1.82%)
QQQ   265.19 (-1.89%)
AAPL   452.04 (+3.32%)
MSFT   209.19 (+2.86%)
FB   259.89 (+1.47%)
GOOGL   1,507.24 (+1.80%)
AMZN   3,162.24 (+2.65%)
NVDA   457.61 (+5.44%)
CGC   17.25 (+1.77%)
BABA   255.19 (+2.73%)
TSLA   1,554.76 (+13.12%)
GE   6.72 (-0.15%)
MU   48.48 (+1.51%)
AMD   82.61 (+7.45%)
T   30.18 (-0.07%)
F   7.11 (-1.66%)
ACB   9.80 (-2.20%)
GILD   68.84 (+1.09%)
NFLX   475.47 (+1.83%)
DIS   131.79 (+1.00%)
BAC   26.73 (-0.71%)
BA   175.44 (-2.60%)
S&P 500   0.67 (+1.82%)
DOW   0.67 (+1.82%)
QQQ   265.19 (-1.89%)
AAPL   452.04 (+3.32%)
MSFT   209.19 (+2.86%)
FB   259.89 (+1.47%)
GOOGL   1,507.24 (+1.80%)
AMZN   3,162.24 (+2.65%)
NVDA   457.61 (+5.44%)
CGC   17.25 (+1.77%)
BABA   255.19 (+2.73%)
TSLA   1,554.76 (+13.12%)
GE   6.72 (-0.15%)
MU   48.48 (+1.51%)
AMD   82.61 (+7.45%)
T   30.18 (-0.07%)
F   7.11 (-1.66%)
ACB   9.80 (-2.20%)
GILD   68.84 (+1.09%)
NFLX   475.47 (+1.83%)
DIS   131.79 (+1.00%)
BAC   26.73 (-0.71%)
BA   175.44 (-2.60%)
S&P 500   0.67 (+1.82%)
DOW   0.67 (+1.82%)
QQQ   265.19 (-1.89%)
AAPL   452.04 (+3.32%)
MSFT   209.19 (+2.86%)
FB   259.89 (+1.47%)
GOOGL   1,507.24 (+1.80%)
AMZN   3,162.24 (+2.65%)
NVDA   457.61 (+5.44%)
CGC   17.25 (+1.77%)
BABA   255.19 (+2.73%)
TSLA   1,554.76 (+13.12%)
GE   6.72 (-0.15%)
MU   48.48 (+1.51%)
AMD   82.61 (+7.45%)
T   30.18 (-0.07%)
F   7.11 (-1.66%)
ACB   9.80 (-2.20%)
GILD   68.84 (+1.09%)
NFLX   475.47 (+1.83%)
DIS   131.79 (+1.00%)
BAC   26.73 (-0.71%)
BA   175.44 (-2.60%)
S&P 500   0.67 (+1.82%)
DOW   0.67 (+1.82%)
QQQ   265.19 (-1.89%)
AAPL   452.04 (+3.32%)
MSFT   209.19 (+2.86%)
FB   259.89 (+1.47%)
GOOGL   1,507.24 (+1.80%)
AMZN   3,162.24 (+2.65%)
NVDA   457.61 (+5.44%)
CGC   17.25 (+1.77%)
BABA   255.19 (+2.73%)
TSLA   1,554.76 (+13.12%)
GE   6.72 (-0.15%)
MU   48.48 (+1.51%)
AMD   82.61 (+7.45%)
T   30.18 (-0.07%)
F   7.11 (-1.66%)
ACB   9.80 (-2.20%)
GILD   68.84 (+1.09%)
NFLX   475.47 (+1.83%)
DIS   131.79 (+1.00%)
BAC   26.73 (-0.71%)
BA   175.44 (-2.60%)
Log in

NASDAQ:MLNTMelinta Therapeutics Stock Price, Forecast & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
Add
Compare
Today's Range N/A
50-Day Range
$0.35
MA: $0.48
$0.50
52-Week Range N/A
VolumeN/A
Average Volume713,628 shs
Market Capitalization$6.88 million
P/E RatioN/A
Dividend YieldN/A
Beta4.16
Melinta Therapeutics, Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes various anti-infectives for the treatment of bacterial infectious diseases in North America. It offers Baxdela, a monotherapy treatment of adult patients with acute bacterial skin or skin structure infections (ABSSSIs); Vabomere, an IV antibiotic used in treatment of gram-negative infections; Orbactiv, an IV antibiotic of the lipoglycopeptide class for the treatment of adult patients with ABSSSIs; and Minocin, a IV antibiotic of the tetracycline class with activity against gram-positive and gram-negative pathogens. The company has license agreements with Yale University, Medical Research Council, Wakunaga Pharmaceutical Co., Ltd., and CyDex Pharmaceuticals, Inc. Melinta Therapeutics, Inc. was founded in 2000 and is headquartered in New Haven, Connecticut.
Read More
Melinta Therapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.87 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
Current SymbolNASDAQ:MLNT
CUSIP15130J10
Phone908-617-1309

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$96.43 million
Book Value$16.96 per share

Profitability

Net Income$-157,190,000.00
Net Margins-393.39%

Miscellaneous

Employees290
Market Cap$6.88 million
Next Earnings DateN/A
OptionableOptionable

Receive MLNT News and Ratings via Email

Sign-up to receive the latest news and ratings for MLNT and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Melinta Therapeutics (NASDAQ:MLNT) Frequently Asked Questions

Do Wall Street analysts recommend investors buy shares of Melinta Therapeutics?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Melinta Therapeutics in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Melinta Therapeutics
.

How were Melinta Therapeutics' earnings last quarter?

Melinta Therapeutics Inc (NASDAQ:MLNT) released its earnings results on Tuesday, November, 12th. The biotechnology company reported ($15.67) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($2.55) by $13.12. The biotechnology company earned $15.87 million during the quarter, compared to analyst estimates of $15.51 million. Melinta Therapeutics had a negative return on equity of 101.29% and a negative net margin of 393.39%.
View Melinta Therapeutics' earnings history
.

When did Melinta Therapeutics' stock split? How did Melinta Therapeutics' stock split work?

Melinta Therapeutics shares reverse split on Friday, February 22nd 2019. The 1-5 reverse split was announced on Thursday, February 21st 2019. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, February 21st 2019. An investor that had 100 shares of Melinta Therapeutics stock prior to the reverse split would have 20 shares after the split.

Has Melinta Therapeutics been receiving favorable news coverage?

Press coverage about MLNT stock has trended somewhat negative recently, InfoTrie Sentiment reports. The research firm identifies negative and positive press coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Melinta Therapeutics earned a news impact score of -1.2 on InfoTrie's scale. They also assigned news articles about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the near future.
View the latest news about Melinta Therapeutics
.

Who are some of Melinta Therapeutics' key competitors?

What other stocks do shareholders of Melinta Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Melinta Therapeutics investors own include Cara Therapeutics (CARA), Clearside Biomedical (CLSD), Chimerix (CMRX), Aerie Pharmaceuticals (AERI), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Ocular Therapeutix (OCUL), NVIDIA (NVDA), Novavax (NVAX) and Nabriva Therapeutics (NBRV).

Who are Melinta Therapeutics' key executives?

Melinta Therapeutics' management team includes the following people:
  • Dr. Erin M. Duffy, Chief Scientific Officer & Exec. VP (Age 51)
  • Mr. John H. Johnson, CEO & Director (Age 61)
  • Dr. Thomas A. Steitz, Co-Founder
  • Dr. Peter B. Moore Ph.D., Co-Founder
  • Dr. William L. Jorgensen, Co-Founder

What is Melinta Therapeutics' stock symbol?

Melinta Therapeutics trades on the NASDAQ under the ticker symbol "MLNT."

How big of a company is Melinta Therapeutics?

Melinta Therapeutics has a market capitalization of $0.00 and generates $96.43 million in revenue each year. The biotechnology company earns $-157,190,000.00 in net income (profit) each year or ($17.72) on an earnings per share basis. Melinta Therapeutics employs 290 workers across the globe.

What is Melinta Therapeutics' official website?

The official website for Melinta Therapeutics is www.melinta.com.

How can I contact Melinta Therapeutics?

Melinta Therapeutics' mailing address is 44 WHIPPANY ROAD, MORRISTOWN NJ, 07960. The biotechnology company can be reached via phone at 908-617-1309 or via email at [email protected]

This page was last updated on 8/12/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.